Results 141 to 150 of about 189,682 (288)
“A Derelict in the Stream of the Law”: Overruling Baseball’s Antitrust Exemption [PDF]
, 1999 Sullivan, Morgen A.
core +2 more sources
Arthritis Care &Research, EarlyView.Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao +39 more
wiley +1 more source
The Cost of Inaction: A Portrait of Street Beggars in Medan City
, 2023 Indra Muda +3 more
openalex +2 more sources
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Arthritis Care &Research, EarlyView.Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava +48 more
wiley +1 more source
Diffusion‐Weighted Imaging for the Evaluation of the Sacroiliac Joint in Pediatric Patients
Arthritis Care &Research, EarlyView.Objective Maturational signal in the sacroiliac joint (SIJ) of skeletally immature youth is often misinterpreted as inflammation. Diagnostic tools that improve specificity are greatly needed. Apparent diffusion coefficient (ADC) values from diffusion‐weighted imaging (DWI), when used with standard imaging, may enhance diagnostic accuracy.
Michael L. Francavilla +6 more
wiley +1 more source
Effects of 'Action/Inaction' Frame-Fit on Sequential Self-Regulation
, 2015 조혜연, Hoon‐Seok Choi
openalex +1 more source
Managing biological invasions: the cost of inaction [PDF]
, 2022 Danish A. Ahmed +11 more
openalex +1 more source
Arthritis Care &Research, Accepted Article.Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source